Caplacizumab: First Global Approval

被引：174

作者：

Duggan, Sean ^{[1
]}

机构：

[1] Springer, Private Bag 65901, Auckland 0754, New Zealand

来源：

DRUGS | 2018年 / 78卷 / 15期

关键词：

THROMBOTIC THROMBOCYTOPENIC PURPURA; SAFETY; EFFICACY;

D O I：

10.1007/s40265-018-0989-0

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Ablynx, a Sanofi Company, has developed the anti-von Willebrand factor Nanobody (R) caplacizumab (Cablivi) for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). Based on positive results in phase II and III trials in patients with aTTP, caplacizumab was recently approved in the EU for the treatment of adults experiencing an episode of aTTP, in conjunction with plasma exchange and immunosuppression. This article summarizes the milestones in the development of caplacizumab leading to this first approval.

引用

页码：1639 / 1642

页数：4

共 8 条

[1]

Ablynx, 2018, UND NAN

[2] Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura [J].

Callewaert, Filip ;

Roodt, Jan ;

Ulrichts, Hans ;

Stohr, Thomas ;

van Rensburg, Walter Janse ;

Lamprecht, Seb ;

Rossenu, Stefaan ;

Priem, Sofie ;

Willems, Wouter ;

Holz, Josefin-Beate .

BLOOD, 2012, 120 (17) :3603-3610

[3]

European Medicines Agency, 2018, CABL CAP ASS REP

[4]

European medicines agency, 2018, CABL CAPL SUMM PROD

[5] Thrombotic thrombocytopenic purpura [J].

Joly, Berangere S. ;

Coppo, Paul ;

Veyradier, Agnes .

BLOOD, 2017, 129 (21) :2836-2846

[6] Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura [J].

Peyvandi, Flora ;

Scully, Marie ;

Hovinga, Johanna A. Kremer ;

Cataland, Spero ;

Knoebl, Paul ;

Wu, Haifeng ;

Artoni, Andrea ;

Westwood, John-Paul ;

Taleghani, Magnus Mansouri ;

Jilma, Bernd ;

Callewaert, Filip ;

Ulrichts, Hans ;

Duby, Christian ;

Tersago, Dominique .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (06) :511-522

[7] Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura [J].

Scully, Marie ;

Knoebl, Paul ;

Kentouche, Karim ;

Rice, Lawrence ;

Windyga, Jerzy ;

Schneppenheim, Reinhard ;

Hovinga, Johanna A. Kremer ;

Kajiwara, Michiko ;

Fujimura, Yoshihiro ;

Maggiore, Caterina ;

Doralt, Jennifer ;

Hibbard, Christopher ;

Martell, Leah ;

Ewenstein, Bruce .

BLOOD, 2017, 130 (19) :2055-2063

[8] Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs [J].

Ulrichts, Hans ;

Silence, Karen ;

Schoolmeester, Anne ;

de Jaegere, Peter ;

Rossenu, Stefaan ;

Roodt, Jan ;

Priem, Sofie ;

Lauwereys, Marc ;

Casteels, Peter ;

Van Bockstaele, Femke ;

Verschueren, Katrien ;

Stanssens, Patrick ;

Baumeister, Judith ;

Holz, Josefin-Beate .

BLOOD, 2011, 118 (03) :757-765

← 1 →